Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy

NCT03748979 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03748979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03748979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy
Lead sponsor
Takeda
Phase
Phase 1
Overall status
Completed
Start date
November 21, 2018
Completion date
October 24, 2019
Enrollment
57 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants, narcolepsy